Page 123 - Demo

ANALESRANFwww.analesranf.com26. Real Farmacopea Espa%u00f1ola (2010) 2.9.7. Friabilidadde los comprimidos no recubiertos. [Internet].[citado 22 de abril de 2020]. Disponible en:https://extranet.boe.es/farmacopea/doc.php?id=2090727. Real Farmacopea Espa%u00f1ola (2011) 2.9.1.Disgregaci%u00f3n de comprimidos y c%u00e1psulas.[Internet]. [citado 24 de abril de 2020].Disponible en:https://extranet.boe.es/farmacopea/doc.php?id=2090128. Real Farmacopea Espa%u00f1ola (2012) 2.9.3. Ensayo dedisoluci%u00f3n de las formas farmac%u00e9uticas s%u00f3lidas.[Internet]. [citado 24 de abril de 2020].Disponible en:https://extranet.boe.es/farmacopea/doc.php?id=2090329. Ficha t%u00e9cnica Prandin 2 mg comprimidos. [Internet].Disponible en:https://cima.aemps.es/cima/pdfs/ft/00162016/FT_00162016.pdf30. Ficha t%u00e9cnica Novonorm 2 mg comprimidos.[Internet]. Disponible en:https://cima.aemps.es/cima/dochtml/ft/98076019/FT_98076019.html31. Rao MEB, Swain S, Patra CN, Sruti J, Patra S.Development and in vitro evaluation of floatingmultiparticulate system of repaglinide. FABAD JPharm Sci. 2011;36(2):75-92.32. Chadha R, Bhandari S, Arora P, Chhikara R.Characterization, quantification and stability ofdifferently prepared amorphous forms of someoral hypoglycaemic agents. Pharm Dev Technol.2013;18(2):504-14.33. Aram%u0103 C, Nicolescu C, Nedelcu A, Monciu CM.Synthesis and characterization of the inclusioncomplex between repaglinide andsulfobutylether-%u03b2-cyclodextrin (Captisol%u00ae). J InclPhenom Macrocycl Chem. 2011;70(3-4):421-8.34. Su M, Xia Y, Shen Y, Heng W, Wei Y, Zhang L, et al. Anovel drug%u2013drug coamorphous system withoutmolecular interactions: improve thephysicochemical properties of tadalafil andrepaglinide. RSC Adv. 2020;10(1):565-83.35. Prieto Chac%u00f3n EM. Estudio de las transicionest%u00e9rmicas del almid%u00f3n y el almid%u00f3n termopl%u00e1sticomediante an%u00e1lisis t%u00e9rmicos (DSC y TGA).Uniandes; 2008.36. Medeiros ACD, Correia LP, Sim%u00f5es MO da S, Mac%u00eadoRO. Technological quality determination ofpharmaceutical disintegrant by DSC cooling andDSC photovisual. J Therm Anal Calorim.2007;88(2):311-5.37. Mahon D, Claudio G, Eames P. An Experimental Studyof the Decomposition and Carbonation ofMagnesium Carbonate for Medium TemperatureThermochemical Energy Storage. Energies.2021;14(5):1316.38. Awasthi R, Kulkarni GT, Ramana MV, de JesusAndreoli Pinto T, Kikuchi IS, Molim Ghisleni DD,et al. Dual crosslinked pectin%u2013alginate network as15. %u00c2ngelo ML, Ruela ALM, Ferreira ACM, Ramos MV deF, Montanari CM, Silva LM da, et al. Evaluatingthe discriminatory power of a dissolution assayfor rosuvastatin calcium capsules: Solid-stateproperties and dissolution media. Braz J PharmSci. 2019;55:e17520.16. V%u00e1zquez D%u00edaz S. Puesta a punto de metodolog%u00edasanal%u00edticas de lactosa en bases l%u00e1cteas [Trabajo deFin de M%u00e1ster]. Universidad de Oviedo; 2017.17. Marini A, Berbenni V, Pegoretti M, Bruni G,Cofrancesco P, Sinistri C, et al. Drug-excipientcompatibility studies by physico-chemicaltechniques. J Therm Anal Calorim.2003;73(2):547-61.18. Belozerova NM, Bilski P, Jarek M, Jenczyk J,Kichanov SE, Kozlenko DP, et al. Exploring themolecular reorientations in amorphousrosuvastatin calcium. RSC Adv.2020;10(55):33585-94.19. Kishore CRP, Mohan GVK. Structural identificationand estimation of Rosuvastatin calcium relatedimpurities in Rosuvastatin calcium tablet dosageform. Anal Chem Res. 2017;12:17-27.20. Su%u00f1e Negre J, Roig Carreras M, Fuster Garc%u00eda R,Hern%u00e1ndez P%u00e9rez C, Ruh%u00ed Roura R, Garc%u00eda MontoyaE, et al. Nueva metodolog%u00eda de preformulaci%u00f3ngal%u00e9nica para la caracterizaci%u00f3n de sustancias enrelaci%u00f3n a su viabilidad para la compresi%u00f3n:Diagrama SeDeM. Cienc Tecnol Pharm. 2005;125-36.21. Su%u00f1e Negre J, Perezlozano P, Minarro M, Roig M,Fuster R, Hernandez C, et al. Application of theSeDeM Diagram and a new mathematicalequation in the design of direct compressiontablet formulation. Eur J Pharm Biopharm.2008;69(3):1029-39.22. Su%u00f1%u00e9 Ne%u0123re JM, Roi%u0123 Carreras M, Garc%u00eda RF, MontoyaEG, Lozano PP, A%u0123uilar JE, et al. SeDeM Diagram:an expert system for preformation,characterization and optimization of tabletsobtained by direct compression. En: FormulationTools for Pharmaceutical Development [Internet].Elsevier; 2013 [citado 26 de diciembre de 2021].p. 109-35. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/B978190756899250005023. Aguilar-D%u00edaz JE, Garc%u00eda-Montoya E, P%u00e9rez-Lozano P,Su%u00f1%u00e9-Negre JM, Mi%u00f1arro M, Tic%u00f3 JR. SeDeM expertsystem a new innovator tool to developpharmaceutical forms. Drug Dev Ind Pharm.2014;40(2):222-36.24. European Pharmacopoeia (2005) 2.9.40. Uniformityof dosage units. content uniformity. [Internet].[citado 28 de junio de 2022]. Disponible en:http://www.uspbpep.com/ep50/2.9.40%20Uniformity%20of%20dosage%20units.pdf.25. Real Farmacopea Espa%u00f1ola (2008) 2.9.8. Resistenciade los comprimidos a la rotura. [Internet].[citado 22 de abril de 2020]. Disponible en:https://extranet.boe.es/farmacopea/doc.php?id=20908Desarrollo gal%u00e9nico de una c%u00e1psula que contieneminicomprimidos de rosuvastatina, repaglinida yolmesartan para el tratamiento del s%u00edndrome metab%u00f3licoRoc%u00edo Gonz%u00e1lez Crespo277 An. R.Acad. Farm.Vol. 90. n%u00ba 2 (2024) %u00b7 pp. 257-278